On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy

Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2 inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Franchini, Massimo, Casadevall, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697776/
https://www.ncbi.nlm.nih.gov/pubmed/36366476
http://dx.doi.org/10.3390/v14112378
_version_ 1784838651785510912
author Focosi, Daniele
Franchini, Massimo
Casadevall, Arturo
author_facet Focosi, Daniele
Franchini, Massimo
Casadevall, Arturo
author_sort Focosi, Daniele
collection PubMed
description Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2 infection, we review here in vitro and in vivo evidence supporting a contributing role for anti-nucleocapsid antibodies. Retrospective investigation of anti-nucleocapsid antibody levels in randomized clinical trials of COVID-19 convalescent plasma is warranted to better understand whether there is an association with efficacy or lack thereof.
format Online
Article
Text
id pubmed-9697776
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96977762022-11-26 On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy Focosi, Daniele Franchini, Massimo Casadevall, Arturo Viruses Opinion Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2 infection, we review here in vitro and in vivo evidence supporting a contributing role for anti-nucleocapsid antibodies. Retrospective investigation of anti-nucleocapsid antibody levels in randomized clinical trials of COVID-19 convalescent plasma is warranted to better understand whether there is an association with efficacy or lack thereof. MDPI 2022-10-27 /pmc/articles/PMC9697776/ /pubmed/36366476 http://dx.doi.org/10.3390/v14112378 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Focosi, Daniele
Franchini, Massimo
Casadevall, Arturo
On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title_full On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title_fullStr On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title_full_unstemmed On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title_short On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
title_sort on the need to determine the contribution of anti-nucleocapsid antibodies as potential contributors to covid-19 convalescent plasma efficacy
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697776/
https://www.ncbi.nlm.nih.gov/pubmed/36366476
http://dx.doi.org/10.3390/v14112378
work_keys_str_mv AT focosidaniele ontheneedtodeterminethecontributionofantinucleocapsidantibodiesaspotentialcontributorstocovid19convalescentplasmaefficacy
AT franchinimassimo ontheneedtodeterminethecontributionofantinucleocapsidantibodiesaspotentialcontributorstocovid19convalescentplasmaefficacy
AT casadevallarturo ontheneedtodeterminethecontributionofantinucleocapsidantibodiesaspotentialcontributorstocovid19convalescentplasmaefficacy

Ejemplares similares